Meteor Biotech selected to deliver keynote talk at Hong Kong International Oncology Forum 2025 (HKIOF)

Dr. Amos Lee, CEO of Meteor Biotech, will open Welcome and Plenary session with presentation on ‘Spatially-resolved Cell Sorting for Precision Oncology’; spotlighting growing importance of spatial omics in cancer research

HKIOF, in conjunction with 9th annual meeting of International Society of Precision Medicine and International Society of Liquid Biopsy Symposium 2025, takes place at Hopewell Hotel, Hong Kong, June 20 – 22, 2025

Seoul, South Korea, June 18, 2025 – Meteor Biotech, a specialized spatial omics technology company producing region-targeted cell sorting devices for advanced biomedical research, today announces that Dr. Amos Lee, CEO of Meteor Biotech, will open the Welcome and Plenary session of the Hong Kong International Oncology Forum 2025 (HKIOF) as the lead presenter.

HKIOF is a landmark event convening the world’s foremost experts in oncology research and clinical practice. This two-day event, taking place on June 20 – 22, highlights the most innovative and impactful advances in the field of oncology. 

Dr. Lee will open the session with a presentation on: ‘Spatially-resolved Cell Sorting for Precision Oncology.’ Its selection as the premier segment emphasizes the relevance of spatial omics in cancer research and therapeutic development. This recognition also underscores the growing importance of spatial omics in translational medicine.

“It is an honor to lead the opening presentation in the Welcome and Plenary session at HKIOF,” said Dr. Lee. “Being featured in this high-profile session — which includes only two presentations and a live panel discussion — reflects both the scientific merit of our work and the increasing demand for technologies that bridge spatial biology and actionable insights in disease research.”

Spatial omics is emerging as an essential tool in enabling far deeper analysis of tumors and understanding the complex interplay and functional evolution among cells. Meteor Biotech’s unique approach to region-targeted cell isolation allows researchers in precision oncology to gain new insights at the single-cell and sub-cellular level, which could help guide the progress of precision medicine, targeted therapies and personalized treatments.

Since Meteor Biotech’s founding in 2022 and development of its flagship device CosmoSort, this unique spatial cell sorter that brings an unprecedented level of precision to tissue analysis has gained increasing attention from prestigious research institutes and adoption among leading academics and clinicians.

To support this growing interest, Meteor Biotech recently opened its first US site at UCLA, a hub for scientific collaboration and innovation. This new office is designed as a hands-on center for demonstration, training and pilot research, with a focus on cancer, neurodegenerative disease, immunology and biomarker discovery.

Presentation at HKIOF:

Title: Spatially-resolved Cell Sorting for Precision Oncology

Session: Welcome and Plenary Session

20 min presentation x 2

20 min introduction + panel discussion

Date: Friday, June 20, 2025

Time: 09:00 to 10:00

Place: Crystal Court

About Meteor Biotech

Meteor Biotech is a specialized spatial omics technology company producing region-targeted cell sorting devices for advanced bioresearch analysis, including genomics, transcriptomics and proteomics. A spin-off from Seoul National University and leveraging over a decade of research and engineering, Meteor developed its proprietary platform technology, SLACS (Spatially-resolved Laser-Activated Cell Sorting), with which it has pioneered the world’s first spatial cell sorter, CosmoSort. CosmoSort enables researchers to sort specific regions of interest from tissue sections with high spatial precision, supporting a wide range of applications in cancer biology, immunology and neuroscience, among others. By empowering scientists to both observe and retrieve spatially defined cells, CosmoSort transforms static imaging into dynamic discovery — enabling researchers to translate spatial insights into deeper, more actionable biological understanding.

Founded in 2022, Meteor Biotech has raised over $60M in funding, predominantly in grants. The company, headquartered in South Korea, currently commercializes CosmoSort, its award-winning device, in Asia and North America, with plans to expand into Europe.

www.meteorbiotech.com